Fixed Income - The secondary market for credit bonds has seen significant activity due to structural interest rate cuts and excess MLF renewals, leading to a notable increase in trading volume [2][9] - The average issuance rate for AA city investment bonds, AA+ industrial bonds, and financial bonds has increased significantly, while the issuance rates for other credit bonds have fluctuated within 10 basis points [10] - The yield on credit bonds has continued to decline, with various types of credit bonds experiencing a reduction in spreads, making coupon-bearing assets increasingly scarce [12] Construction and Building Materials - Infrastructure investment has turned negative for the first time since 2004, with narrow and broad infrastructure completing 18.08 trillion yuan and 24.50 trillion yuan respectively in 2025, showing declines of -2.20% and -1.48% year-on-year [14][15] - New orders in the construction sector are characterized by stability among central enterprises, regional differentiation, and strong overseas demand, with major state-owned enterprises maintaining high order volumes [15][16] - The outlook for infrastructure investment is expected to stabilize and recover gradually, supported by major strategic projects and policy measures [14] Aerospace Industry - SpaceX plans to launch its second-generation Starlink satellite communication system in 2027, which will significantly enhance capacity and data throughput compared to the first generation [21][22] - The global rocket launch service market is projected to exceed $50 billion by 2032, with a compound annual growth rate of 13% from 2023 to 2032 [21] - Six companies in the North Exchange's rocket industry chain have been identified, indicating a growing interest in this sector [21] Pharmaceutical Industry - The introduction of service price guidelines for surgical robots is expected to accelerate the development of the surgical robot industry in China [27][28] - The pharmaceutical market has shown mixed performance, with a focus on innovative drugs and medical technologies such as AI and brain-computer interfaces [25][29] - Key companies to watch include China Biologic Products, Shanghai Yizhong, and Fuyuan Pharmaceutical, among others, as they are expected to benefit from industry trends [30] Media and Internet - Kuaishou's AI video generation model has surpassed 12 million monthly active users, highlighting the growing importance of AI in the media sector [32][37] - The AI sector remains a critical narrative in the global industry, with significant investments in AI marketing, content generation, and e-commerce applications [32] - Companies such as Tencent, Alibaba, and ByteDance are expected to lead in AI product development and commercialization [32]

Group 1 - Lianyungang City, Haizhou District aims to establish a modern urban center with a target of 100 billion yuan, focusing on major project construction and investment attraction from the beginning of the year [1] - In the first quarter, 85 projects are planned to start, with 37 industrial projects already underway, including 74 projects in medical consumables R&D and manufacturing, aiming for completion within the year [1] - The district is enhancing production capacity through accelerated project implementation, which is expected to strengthen the foundation for high-quality development [1] Group 2 - The Zhengda Tianqing comprehensive formulation production project is progressing with 65% completion, focusing on enhancing core production capacity, with specific areas nearing completion [1] - The Circular Economy Industrial Park project in Xinpux Industrial Park covers 117 acres with a total investment of approximately 500 million yuan, aiming to process 100,000 tons of renovation waste and 50,000 tons of demolition waste annually [2] - Jiangsu Yingyou Textile Machinery is leveraging 40 years of technology to produce SCARA robot components, with plans to deepen the integration of innovation and industry [2] Group 3 - Haizhou District emphasizes precise investment attraction and efficient service, with over 90 "invitation" events and 15 "outreach" events conducted to gather quality resources [3] - The district's development and reform bureau and industry and information bureau have formed service teams to address enterprise needs, including labor and financing challenges [3] - The district is committed to creating a favorable business environment to ensure project success and sustainable development [3]

Core Viewpoint - The Hong Kong stock market is experiencing a downturn, particularly in the innovative drug sector, with the Hong Kong Stock Connect Innovative Drug ETF (520880) declining by 1.5% on January 26, despite a positive buying attitude reflected in high premiums [1][3]. Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) has seen a cumulative decline of 3.2% over the past week, with over 236 million yuan in funds being used to buy on dips [1]. - Major stocks in the sector are experiencing widespread declines, with leading companies such as CSPC Pharmaceutical falling by 3%, and Innovent Biologics dropping nearly 4% [1]. Group 2: Industry Transactions - Several innovative drug business development (BD) transactions have been completed at the beginning of the year, indicating a positive trend for Chinese innovative drugs going overseas. Key transactions include: 1. Rongchang Biologics granting AbbVie overseas rights for RC148 (PD-1/VEGF) dual antibody, receiving a $650 million upfront payment and up to $4.95 billion in milestone payments [3]. 2. Haisco granting overseas rights for HSK39004 (PDE3/4) to AirNexis, with an upfront payment of $108 million and up to $955 million in milestone payments [3]. 3. Zai Lab granting AbbVie overseas rights for ZG006 (CD3xDLL3xDLL3 tri-antibody), receiving a $100 million upfront payment and milestone payments totaling $1.135 billion [3]. 4. Yilian Biologics granting Roche overseas rights for YL201 (B7-H3ADC), with upfront and near-term milestone payments totaling $570 million [3]. Group 3: Investment Opportunities - Investors are encouraged to consider core assets in innovative drugs during market dips, with a focus on the high elasticity T+0 tool, the Hong Kong Stock Connect Innovative Drug ETF (520880), and its associated funds [3]. - The index for the ETF (Hang Seng Hong Kong Stock Connect Innovative Drug Select Index) has three unique advantages: 1. 100% purity, covering only innovative drug R&D companies [3]. 2. A significant concentration of leading companies, with the top ten innovative drug leaders accounting for over 73% of the index [4]. 3. Better risk control through forced de-weighting of less liquid constituent stocks [5].

Group 1 - The Hong Kong stock market is experiencing a downturn, with the innovative drug sector declining again, as evidenced by the Hong Kong Stock Connect Innovative Drug ETF (520880) falling by 1.5% [1][6] - Last week, the ETF accumulated a total decline of 3.2%, with over 236 million yuan in funds being used to buy on dips [1][6] - Major stocks in the sector are generally down, including CSPC Pharmaceutical Group down 3%, CanSino Biologics down nearly 4%, and China Biologic Products and Innovent Biologics both down over 2% [1][6] Group 2 - Multiple innovative drug business development (BD) transactions have been completed at the beginning of the year, indicating a positive trend for Chinese innovative drugs going overseas [8] - Key transactions include: 1) Rongchang Biologics granting AbbVie overseas rights for RC148 (PD-1/VEGF) dual antibody, receiving a $650 million upfront payment and up to $4.95 billion in milestone payments [8] 2) Haisco granting overseas rights for HSK39004 (PDE3/4) to AirNexis, receiving a $108 million upfront payment and up to $955 million in milestone payments [8] 3) Zai Lab granting AbbVie overseas rights for ZG006 (CD3xDLL3xDLL3 tri-antibody), receiving a $100 million upfront payment and milestone payments totaling $1.135 billion [8] 4) Yilian Biologics granting Roche overseas rights for YL201 (B7-H3ADC), with upfront and milestone payments reaching $570 million [8] Group 3 - The Hong Kong Stock Connect Innovative Drug ETF (520880) and its associated funds are highlighted as high-elasticity investment tools, with the underlying index (Hang Seng Stock Connect Innovative Drug Select Index) offering three unique advantages [9] - The ETF has a 100% purity, excluding CXO, and fully covers innovative drug R&D companies [9] - The top ten innovative drug leaders account for over 73% of the ETF, showcasing the strength of the innovative drug sector [9][10]

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry as of January 26, 2026 [1] Core Insights - The report emphasizes the importance of supply-side variables, particularly the operating rates of raw material drugs, and highlights the potential for price recovery in the antibiotic market due to changes in competition and supply dynamics [2] - Multi-departmental policy support is enhancing the value positioning of pharmacies, transforming them from mere sales points to comprehensive health service platforms [3] - The trend of Chinese innovative drugs going global is gaining momentum, with significant licensing deals and the need for continuous clinical data validation to support long-term investment confidence [4] - Major companies are increasingly investing in the small nucleic acid field, which is expected to accelerate the development of the supporting industrial chain [5] - A new pricing system for GLP-1 drugs is forming in China, with significant market potential anticipated for weight loss and diabetes treatments [6] - The report highlights the market value of oral autoimmune drugs, with promising clinical trial results for new treatments [7] Summary by Sections 1. Pharmaceutical Market Tracking - The pharmaceutical industry outperformed the CSI 300 index by 0.23 percentage points in the last week, ranking 27th among 31 sectors [20] 2. Pharmaceutical Sector Trends and Valuation - The pharmaceutical sector index increased by 4.98% over the past month, outperforming the CSI 300 index by 3.21 percentage points [37] - The current PE (TTM) for the pharmaceutical sector is 38.51, above the five-year historical average of 31.06 [43] 3. Recent Research Achievements - The report includes various deep-dive studies on topics such as the growth of the blood products industry and the potential of GLP-1 drugs [45] 4. Recent Industry Policies and News - Recent policies include the promotion of high-quality development in the pharmaceutical retail sector and the approval of numerous medical devices by the National Medical Products Administration [46][48]

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry as of January 26, 2026 [1] Core Insights - The report emphasizes the importance of supply-side variables, particularly the operating rates of raw material drugs, and highlights the potential for price recovery in the antibiotic market due to changes in competition and supply dynamics [2] - Multi-departmental policy support is enhancing the value positioning of pharmacies, transforming them from mere sales points to comprehensive health service platforms [3] - The trend of Chinese innovative drugs going global is gaining momentum, with significant licensing deals and the need for continuous clinical data validation to support long-term investment confidence [4] - Major companies are increasingly investing in the small nucleic acid field, which is expected to accelerate the development of the supporting industrial chain [5] - A new pricing system for GLP-1 drugs is forming in China, with expectations for market growth driven by a large patient population [6] - The report highlights the market value of oral autoimmune drugs, with promising clinical trial results for new treatments [7] Summary by Sections 1. Pharmaceutical Market Tracking - The pharmaceutical industry outperformed the CSI 300 index by 0.23 percentage points in the last week, ranking 27th among 31 sectors [20] 2. Pharmaceutical Sector Trends and Valuation - The pharmaceutical sector index increased by 4.98% over the past month, outperforming the CSI 300 index by 3.21 percentage points [37] - The current PE (TTM) for the pharmaceutical sector is 38.51, above the five-year historical average of 31.06 [43] 3. Recent Research Achievements - The report includes various deep-dive studies on topics such as the growth of the blood products industry and the impact of policies on inhalation formulations [45] 4. Recent Industry Policies and News - Recent policies include the approval of numerous medical device registrations and the promotion of high-quality development in the pharmaceutical retail sector [46][48]

Market Overview - Global markets showed mixed performance, with the Hang Seng Index closing at 26,750, up 0.45% year-to-date, while the US Dow Jones fell by 0.58% [1][3] - The Chinese stock market saw gains, particularly in materials, consumer discretionary, and healthcare sectors, while energy and real estate lagged [3] Industry Insights - The Chinese pharmaceutical sector is experiencing a significant upward trend, with the MSCI China Healthcare Index rising 9.2% since early 2026, outperforming the MSCI China Index by 5.6% [4] - The trend of Chinese innovative drugs going overseas continues to gain momentum, with multiple business development (BD) transactions occurring in early 2026, indicating a strong market for overseas licensing [5] - Key transactions include the overseas rights granted by Rongchang Biopharma to AbbVie for RC148 and by Haisika for HSK39004, showcasing the clinical progress of these drugs [5] Company Analysis - China Ping An is projected to see a 12% increase in operating profit to RMB 135.9 billion in 2025, driven by improvements in life and health insurance segments [7] - The new business value (NBV) is expected to grow by 42% year-on-year to RMB 40.4 billion, with a strong performance anticipated in the first quarter of 2026, particularly in the bancassurance channel [8] - The target price for China Ping An has been raised to HKD 90, reflecting adjustments in profit and NBV growth forecasts, with the company currently trading at 0.71 times FY26E P/EV [8]

Investment Rating - The report assigns a "Buy" rating to several companies in the pharmaceutical sector, indicating a potential upside of over 15% in their stock prices over the next 12 months [29]. Core Insights - The MSCI China Healthcare Index has increased by 9.2% since the beginning of 2026, outperforming the MSCI China Index, which rose by 5.6% [1]. - The pharmaceutical industry has seen significant growth, driven by strong institutional investor interest and the ongoing trend of innovative drugs going global [1]. - The report emphasizes the importance of clinical progress and data validation for pipelines that have already gone overseas, suggesting that this trend will continue in the long term [1]. Summary by Sections Industry Overview - The report highlights a robust trend in the outbound licensing of innovative drugs, with multiple business development (BD) transactions occurring at the start of 2026, reflecting a high level of activity in the sector [4]. - Key transactions include significant upfront and milestone payments for various drugs, indicating strong market interest and potential for future growth [4]. Company Ratings and Valuations - The report provides detailed valuations for several companies, including: - **Sangfor Technologies (1530 HK)**: Market cap of $7,598.4 million, target price of $37.58, with a 54% upside potential [2]. - **Gusongtang (2273 HK)**: Market cap of $963.3 million, target price of $44.95, with a 46% upside potential [2]. - **WuXi AppTec (2268 HK)**: Market cap of $10,551.0 million, target price of $88.00, with a 28% upside potential [2]. - **China National Pharmaceutical Group (1177 HK)**: Market cap of $15,951.4 million, target price of $9.40, with a 42% upside potential [2]. Market Trends - The report notes that the competition in the PD-(L)1/VEGF space is intensifying, with several companies advancing their clinical trials and aiming for first-line indications [4]. - The report suggests that the efficiency and breadth of clinical trials, as well as the richness of combination therapies, will be critical factors in determining success in this competitive landscape [4].

Investment Rating - The investment rating for the pharmaceutical industry is "Positive" (maintained) [4] Core Insights - The report highlights the potential acceleration of the surgical robot industry following the release of the service pricing guidelines by the National Medical Insurance Administration, which clarifies the pricing structure for surgical robot services and consumables [3][18] - The report emphasizes the importance of innovation in the pharmaceutical sector, noting that the industry has completed a transition from old to new growth drivers, particularly in innovative drugs, which are expected to continue to perform well in 2026 [46][47] - The report suggests a focus on sectors such as innovative drugs, AI medical technology, and brain-computer interfaces, which are anticipated to see significant advancements in 2026 [46][48] Summary by Sections Market Performance - From January 19 to January 23, the pharmaceutical index decreased by 0.39%, with an excess return of 0.23% relative to the CSI 300 index. The market was relatively stable, with a notable increase of 1.26% on Friday, driven by themes like brain-computer interfaces and AI medical technology [5][27] - A total of 330 stocks rose while 137 fell during the week, with notable gainers including *ST Changyao (+70.37%) and Hualan Biological (+32.21%) [27][28] Surgical Robot Industry - The surgical robot market is expected to benefit from the new pricing guidelines, which will enhance the clinical application of surgical robots and promote a sustainable business model [3][18] - The domestic laparoscopic robot market is projected to grow significantly, with a compound annual growth rate (CAGR) of 29.3% from 2024 to 2030 [9][15] Investment Recommendations - The report recommends focusing on strong fundamentals and well-adjusted innovative drug stocks, including companies like Xinlitai, Zexing Pharmaceutical, and Hengrui Medicine, as well as medical technology firms like Yuyue Medical and Alibaba Health [5][49] - It also suggests monitoring companies involved in the export of CXO services and those with stable operations and low valuations that are expected to see fundamental changes in 2026 [5][46] Future Outlook - The report anticipates that the pharmaceutical industry will continue to improve marginally in 2026, driven by technological innovation and performance recovery in traditional sectors [46][47] - Key areas of focus include innovative drugs, AI medical technology, and the aging population's healthcare needs, which are expected to drive demand [46][48]

Market Performance - After a six-day decline, the Hong Kong Stock Connect Innovation Drug ETF (520880) rebounded on January 23, rising over 2% at one point and closing up 1.53% with a trading volume of 348 million yuan [1][6] - Major constituent stocks such as Cloudtop New Drug led the gain with an 8.2% increase, while other key stocks like Kangfang Biotech and Shiyao Group also saw positive performance [1][6] Policy Impact - On January 22, the Ministry of Commerce and nine other departments issued a document promoting high-quality development in the pharmaceutical retail sector, encouraging innovative drugs and reference preparations to enter retail pharmacy sales channels [3][9] - This policy is expected to provide a pathway for high-value innovative drugs, such as CAR-T, to fill the insurance coverage gap through commercial insurance directories [3][9] - The insurance industry association estimates that by 2025, the total compensation amount for innovative drugs and devices from commercial health insurance will reach approximately 14.7 billion yuan, with a compound annual growth rate of 70% over four consecutive years [3][9] Industry Trends - At the recent JPM conference, Chinese pharmaceutical companies showcased technological breakthroughs in areas such as ADC, IO dual antibodies, and GLP-1, moving towards global markets through licensing and collaborative development [3][9] - According to CITIC Securities, the Chinese pharmaceutical industry is at the starting point of a global value reassessment, with 2026 being a critical year for validating transformation effectiveness [3][9] Investment Opportunities - The Hong Kong Stock Connect Innovation Drug ETF (520880) is highlighted as a high-elasticity T+0 investment tool, with its index featuring three unique advantages: 1. Purely innovative drugs with 100% purity, covering companies focused on drug development [5][11] 2. A significant concentration of leading companies, with the top ten innovative drug leaders accounting for over 73% of the index [5][11] 3. Enhanced risk control through forced de-weighting of less liquid constituent stocks [5][11] Constituent Stocks - The top ten constituent stocks of the Hong Kong Stock Connect Innovation Drug ETF (520880) have a combined weight of 73.41%, showcasing significant leadership in the sector [6][12] - Notable stocks include: - Kangfang Biotech (10.49% weight, market cap of 110.9 billion HKD) - Baijie Shenzhou (10.01% weight, market cap of 312 billion HKD) - Shiyao Group (9.97% weight, market cap of 102.1 billion HKD) [6][12]